Table: Santen Pharm -9-MTH group results (IFRS)

SANTEN PHARMACEUTICAL

07/02/2017 06:00

Feb 7 (Reuters)-  
              Santen Pharmaceutical Co Ltd  
              CONSOLIDATED FINANCIAL HIGHLIGHTS  
     (in billions of yen unless specified)  
                   9 months ended      9 months ended       Year to  
                  Dec 31, 2016        Dec 31, 2015     Mar 31, 2017  
                     LATEST             YEAR-AGO          COMPANY    
                     RESULTS             RESULT          FORECAST    
  Sales              150.67              149.20           200.00     
                   (+1.0 pct)          (+27.7 pct)      (+2.4 pct)   
  Operating           27.49               74.42            36.30     
                   (-63.1 pct)        (+186.3 pct)      (-54.7 pct)  
  Pretax              26.79               74.46            36.50     
                   (-64.0 pct)        (+183.1 pct)      (-54.1 pct)  
  Net                 19.81               49.89            25.30     
                   (-60.3 pct)        (+189.0 pct)      (-52.6 pct)  
  EPS Basic         48.12 yen          120.59 yen        61.09 yen   
  EPS Diluted       47.94 yen          120.04 yen                    
  Ann Div                               25.00 yen        26.00 yen   
  -Q2 Div           13.00 yen           12.00 yen                    
  -Q4 Div                               13.00 yen        13.00 yen   
  
  NOTE - Santen Pharmaceutical Co Ltd.  
  (Figures are reported based on international accounting rules (IFRS).)  
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half  
  dividend and Q4 to the second-half dividend announced before a new corporate law in  
  2006 allowed companies to pay and report dividends on a quarterly basis. 
  *Net - represents Net profit attributable to owners of the parent company.  
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T  
  ((Tokyo Headline News Desk +813 6441 1812))